Urinary neopterin concentration and toxicity of radiotherapy in patients with head and neck carcinoma during external beam radiation.

AIM Increased serum or urinary concentrations of neopterin are predictive of poor prognosis in patients with tumors across a spectrum of primary locations. Less information is available about the significance of changes of urinary neopterin concentrations during therapy. The aim of the present study was to examine the association between urinary neopterin and toxicity of radiotherapy. PATIENTS AND METHODS We analyzed changes of urinary neopterin and toxicity of therapy in 12 patients with head and neck carcinoma during external-beam radiation. Urinary neopterin was determined daily by high-performance liquid chromatography. RESULTS In addition to a trend for increased neopterin concentrations during radiation therapy, a significant association between changes of neopterin and toxicity and vice versa was observed with a rise of neopterin predicting a later manifestation of toxicity as well as manifestion of toxicity predicting a later rise of neopterin. CONCLUSION Urinary neopterin is predictive of toxicity in patients with head and neck carcinoma. An association between toxicity and subsequent rise of urinary neopterin concentrations was also observed.

[1]  B. Melichar,et al.  Prognostic significance of serum retinol, serum alpha-tocopherol, and urinary neopterin in patients with head and neck carcinoma treated with external beam radiation. , 2012, International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition.

[2]  B. Melichar,et al.  Article in press-uncorrected proof Editorial Laboratory medicine : an essential partner in the care of cancer patients , 2011 .

[3]  Christopher U. Jones,et al.  Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.

[4]  B. Melichar,et al.  Intestinal Permeability in the Assessment of Intestinal Toxicity of Cytotoxic Agents , 2005, Chemotherapy.

[5]  D. Sidransky,et al.  Head and neck cancer. , 2001, The New England journal of medicine.

[6]  B. Melichar,et al.  Biochemical profile and survival in nonagenarians. , 2001, Clinical biochemistry.

[7]  H. Wachter,et al.  Neopterin as a prognostic parameter in patients with squamous‐cell carcinomas of the oral cavity , 1998, International journal of cancer.

[8]  B. Melichar,et al.  Mitogen-induced lymphocyte proliferation and systemic immune activation in cancer patients. , 1996, Tumori.

[9]  B. Melichar,et al.  Increased urinary neopterin in acute myocardial infarction. , 1994, Clinical chemistry.

[10]  H Wachter,et al.  Neopterin as a prognostic indicator in patients with carcinoma of the uterine cervix. , 1986, Cancer research.

[11]  A. Jankowska,et al.  Clinical Usefulness of Determining the Concentration of Neopterin , 2011 .

[12]  Lenka Kujovská Krčmová,et al.  Urinary Neopterin in Patients with Metastatic Colon Cancer Treated with Patupilone , 2011 .

[13]  B. Melichar,et al.  Serial Urinary Neopterin Measurements Reflect the Disease Course in Patients with Epithelial Ovarian Carcinoma Treated with Paclitaxel/Platinum Chemotherapy , 2007 .

[14]  B. Melichar,et al.  Systemic Immune Activation, Anemia and Thrombocytosis in Breast Cancer Patients Treated by Doxorubicin and Paclitaxel , 2006 .

[15]  B. Melichar,et al.  Neopterin as an indicator of immune activation and prognosis in patients with gynecological malignancies , 2004, International Journal of Gynecologic Cancer.

[16]  Bohuslav Melichar,et al.  Urinary Neopterin in Patients with Ovarian Cancer , 2006 .

[17]  B. Melichar,et al.  Urinary Neopterin in Patients with Advanced Colorectal Carcinoma , 2006, The International journal of biological markers.

[18]  P. Kralickova,et al.  CD4+ T-lymphocytopenia and systemic immune activation in patients with primary and secondary liver tumours. , 2001, Scandinavian journal of clinical and laboratory investigation.

[19]  E. Werner,et al.  Neopterin as a marker for activated cell-mediated immunity: application in malignant disease. , 1991, Cancer detection and prevention.

[20]  S. Taylor.  Head and neck cancer. , 1991, Cancer chemotherapy and biological response modifiers.

[21]  E. Werner,et al.  Neopterin as marker for activation of cellular immunity: immunologic basis and clinical application. , 1989, Advances in clinical chemistry.